Abstract: Glaucoma is the leading cause of irreversible blindness worldwide. An increased intraocular pressure (IOP) is known as major risk factor. Currently, drainage devices that are implanted by means of minimally invasive glaucoma surgery (MIGS) represent a promising approach for IOP lowering. Commercially available devices for MIGS suffer from unregulated drainage involving ocular hypotony. Furthermore, long term drainage capability of current devices is limited by fibrotic encapsulation processes. Therefore, our group focusses on the development of a valved drug-eluting microstent for MIGS. Within the current work, we developed two alternative injector devices for minimally invasive microstent implantation. Both injector devices were based on a cannula in which the microstent is loaded and a mandrel inside the cannula. Injector device A is designed to push the microstent out of the cannula and injector device B is designed to withdraw the cannula above the microstent. Manufacturing of injector devices was conducted using rapid prototyping. Simplified polymeric microstents were manufactured from polycarbonate based silicone elastomer. Simulated use was performed in a silicone eye model. The presented injector devices were suitable for minimally invasive ab interno microstent implantation into suprachoroidal space. Ongoing miniaturization of the microstent system will allow the use of a 22 G cannula in future ex vivo experiments.
Introduction
Glaucoma is the leading cause of irreversible blindness worldwide [1] . Characteristic structural damage of the optic nerve and functional visual impairment usually results from increased intraocular pressure (IOP), caused by disturbed aqueous humour dynamics. Recently, a novel generation of glaucoma drainage devices emerged as a promising approach for minimally invasive glaucoma surgery (MIGS) [2] . Commercially available devices for MIGS suffer from unregulated drainage and the resulting risk of ocular hypotony. Furthermore, long term drainage capability of current devices is limited by fibrotic encapsulation processes [3] .
Our group focusses on the development of a valved drug-eluting microstent for MIGS (see Figure 1) . Drainage of aqueous humour from the anterior chamber of the eye into the suprachoroidal space is regulated by means of a micromechanical valve [4] . A drug-eluting coating in the outflow area of the microstent inhibits fibrosis [5] . Within the current work, we developed an injector device for minimally invasive microstent implantation. After measurement of tubing diameter by means of a biaxial laser scanner (ODAC 32 XY, Zumbach Electronic AG, Orpund, Switzerland), dipping mandrels were removed and specimens were dried four days at 40°C in vacuo. Morphological analysis was conducted using environmental scanning electron microscopy (ESEM; Philips XL 30, Philips, Amsterdam, the Netherlands) at a vacuum pressure of 1.2 mbar and an accelerating voltage of 10 kV.
Development of injector devices
Design of two alternative injector devices was developed using Creo Parametric 3.0 (PTC Inc., Needham, MA, USA). Both injector devices were based on a cannula in which the microstent is loaded and a mandrel inside the cannula. Injector device A is designed to push the microstent out of the cannula and injector device B is designed to withdraw the cannula above the microstent (see Figure 2) . Manufacturing of injector devices was conducted using a 3D printer and polylactide filament (Ultimaker 2, Ultimaker B.V., Geldermalsen, Netherlands). For analysis of applicability of injector devices, a simplified two-piece silicone eye model was developed and manufactured based on 3D printed casting molds (see Figure 3 ). 
Results

Manufacturing of microstents
Development of injector devices
Prototypes of the injector devices A and B are shown in Figure 5 . Microstent implantation into the silicone eye model is illustrated in Figure 6 . After paracentesis, the injector device A was inserted into the anterior chamber and advanced to the opposing chamber angle, where the microstent was deployed into suprachoroidal space. Injector device B was advanced beyond the chamber angle and the cannula was withdrawn above the fixed microstent. 
Discussion
The commercially available CyPass System (Alcon, Fort Worth, TX, USA) uses an injector device with a 23 G (OD = 0.60 mm) access for suprachoroidal implantation. As a continuous tube, the CyPass Micro-Stent is fixed on an internal guidewire during implantation. Our microstent concept is based on a micro-mechanical valve for regulation of IOP within physiological boundaries. Since the distal tubing lumen is closed, an internal guidewire is not feasible. Therefore we used a cannula as external guidance.
The presented injector devices were suitable for minimally invasive ab interno microstent implantation into the suprachoroidal space. Allowing an exact guidance of the microstent, injector device B represents the preferred approach. Ongoing miniaturization of our microstent will enable the use of a 22 G (ID = 0.47 mm, OD = 0.70 mm) cannula in future ex vivo implanttations. 
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